It could be a major new player in a large market.

This treatment is now in late-stage testing ahead of potential FDA review.

A proprietary extended-release oral minoxidil, VDPHL01, shows superior efficacy and a consistent safety profile vs placebo for hair loss in men.

A proprietary extended-release oral minoxidil tablet yielded rapid and robust hair growth in men with pattern hair loss, ...

WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 30, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (ARNA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for ...

FluidCrystal® extended release formulation of zilucoplan achieved rapid and sustained pharmacodynamic inhibition of complement C5 in non-human primates, supporting at least once weekly dosing ...

DUBLIN--(BUSINESS WIRE)--The "Extended Release Injectable Drugs" report has been added to ResearchAndMarkets.com's offering. Chronic conditions require drug administration over long periods of time, ...

The FDA approved an oral extended-release formulation of levodopa and carbidopa known as IPX203 (Crexont) to treat Parkinson's disease, Amneal Pharmaceuticals announced Wednesday. The treatment is a ...

WOODCLIFF LAKE, N.J. and SAN DIEGO, Calif., April 10, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of two Phase 1 registrational ...

Phase I pharmacokinetic study of single agent trametinib in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study. Investigational NEDD8-activating ...

Please provide your email address to receive an email when new articles are posted on . The majority of patients receiving opioid analgesics used immediate-release formulations, regardless of the ...